Purdue Pharma L.P.

CourtUnited States Bankruptcy Court, S.D. New York
DecidedOctober 6, 2025
Docket19-23649
StatusUnknown

This text of Purdue Pharma L.P. (Purdue Pharma L.P.) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Purdue Pharma L.P., (N.Y. 2025).

Opinion

UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK ---------------------------------------------------------------x In re: Chapter 11

PURDUE PHARMA L.P., et al., Case No. 19-23649 (SHL)

Debtors. (Jointly Administered)

---------------------------------------------------------------x MEMORANDUM OF DECISION AND ORDER A P P E A R A N C E S:

AMANDA MORALES Pro se Claimant 205 Calle Del Banco Bernalillo, New Mexico 87004 By: Amanda Morales

DAVIS POLK & WARDWELL LLP Counsel for Debtors and Debtors in Possession 450 Lexington Avenue New York, New York 10017 By: Marshall S. Huebner, Esq. Benjamin S. Kaminetzky, Esq. James I. McClammy, Esq. Eli J. Vonnegut, Esq.

SEAN H. LANE UNITED STATES BANKRUPTCY JUDGE Before the Court are two motions and three letters filed by pro se claimant Amanda Morales (“Ms. Morales”) seeking relief in the Chapter 11 proceedings of Purdue Pharma L.P. and its affiliates (the “Debtors”), including a: (i) motion to take judicial notice [ECF No. 6309] (the “Judicial Notice Motion”);1 (ii) letter regarding the Judicial Notice Motion [ECF No. 7030] (the

1 Unless otherwise indicated, references in this Memorandum of Decision and Order to docket entries on the Case Management/Electronic Case Files (“ECF”) system are to Case No. 19-23649. “Judicial Notice Letter”); (iii) letter regarding the December 2024 Hearing (as defined below) [ECF No. 7036], as amended [ECF No. 7037] (the “Clarification Letter”); (iv) letter regarding additional evidence to be included in the record [ECF No. 7075] (the “Evidence Letter”); (v) motion for stay of the Class Certification Order (as defined herein) then-pending appeal [ECF

No. 7063] (the “Stay Motion”); and (vi) letter objecting to the Debtors’ discharge [ECF No. 6245] (the “Objection to Discharge”) (collectively, the “Current Motions”). The Debtors submitted an opposition to all the above filings [ECF No. 7239] (the “Debtors’ Objection”). For the reasons set forth below, the Court denies the requested relief. BACKGROUND Familiarity with these bankruptcy cases and their history is assumed. See Harrington v. Purdue Pharma L.P., 603 U.S. 204 (2024). Accordingly, the Court will only discuss that history to the extent it is necessary for the pending matters. These cases were filed in 2019 after Debtor Purdue Pharma L.P. faced a wave of litigation for its role in the opioid epidemic. See id. at 209. Ms. Morales has participated in these Chapter 11 proceedings since their inception and she has

sought, on numerous occasions, to have the merits of her claim against the Debtors adjudicated.2 Ms. Morales’ claim against the Debtors is based upon the death of her father arising from serotonin syndrome following the interaction of OxyContin and antidepressants. See Complaint [ECF No. 6148] (the “Motion for Summary Judgment”).3 In connection with her efforts to

2 The Honorable Robert D. Drain presided over these Chapter 11 cases from their filing on September 15, 2019, until July 1, 2022. See Notice of Case Reassignment From Judge Robert D. Drain to Judge Sean H. Lane [ECF No. 4937]. Ms. Morales filed her first motion in these proceedings on July 14, 2021. See Plaintiff’s Motion for Summary Judgment [ECF No. 3191] (the “Motion Requesting Summary Judgment”). 3 Although Ms. Morales labeled this filing a “Complaint,” the Court construed this pleading as a motion for summary judgment because no adversary proceeding was ever commenced and the “complaint” was never served on the Debtors with a summons, as required by Federal Rule of Civil Procedure 3. See FED. R. CIV. PRO. 3 (explaining the procedure for commencing an action, which starts by the filing of a complaint, followed by “issuance of a summons and its delivery to an officer for service”); see also Debtors’ Objection at 6–7. adjudicate her claim on the merits, Ms. Morales has filed various motions, objections, and letters, and has been heard at various hearings throughout these proceedings. The Court has frequently explained to Ms. Morales that payment of her claim before the effective date (the “Effective Date”) of the Debtors’ Chapter 11 plan of reorganization (the “Plan”)4 would violate the

fundamental principles of the Bankruptcy Code of similar treatment of claims and the resolution and treatment of general unsecured claims all together under a Chapter 11 plan. See, e.g., Order Denying Motion for Immediate Claim Payment, at 1–2 [ECF No. 2145]; see also Order Denying Motions for Immediate Claim Payment & to Lift Automatic Stay, at 1 [ECF No. 2306]. Despite the Court’s repeated efforts to explain to Ms. Morales that it is not the proper time to adjudicate her claim on the merits, Ms. Morales has continued to file motions, objections, and letters that— while packaged in different forms—ultimately seek the same thing: to adjudicate her individual claim on the merits ahead of the hundreds of thousands of other personal injury claimants in these proceedings. See Debtors’ Objection, Appendix A for a comprehensive list of the various papers submitted by Ms. Morales in these proceedings; see also Amended Disclosure Statement

for Thirteenth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and its Affiliated Debtors Art. I, § C, ¶ 2 (the “Disclosure Statement”) [ECF No. 7609] (explaining that over 614,000 proofs of claims have been filed in these Chapter 11 cases). The most recent of Ms. Morales’ filings, including the Judicial Notice Motion, Judicial Notice Letter, Clarification Letter, Stay Motion, and Evidence Letter, were heard at the February 25, 2025 omnibus hearing (the “February 2025 Hearing”). At the February 2025 Hearing, the Court again explained to Ms. Morales that her claim, while “based on a slightly different set of circumstances [than some other claimants]. . . i[s] still a claim against the Debtor[s]” to be dealt

4 The Debtors’ Plan, as amended, was filed on July 1, 2025. See Thirteenth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and its Affiliated Debtors [ECF No. 7636]. with together with all the hundreds of thousands of other general unsecured claims against the Debtors, as part of the Debtors’ proposed Plan, which is scheduled for confirmation in November 2025. Hr’g Tr., February 25, 2025, at 72:4–73:22, 75:24–76:19, 77:13–24, 79:17–23 [ECF No. 7285]. Put another way, the Court explained that while every claim has its own “individual

story,” her request for recovery now on her claim is problematic because her claim must be “deal[t] with [together with] all the [other] claims that have been filed” against the Debtors through a plan of reorganization. Id. at 76:2–13. The Court further made clear that, by waiting for the confirmation hearing on the Debtors’ Plan and the related dissemination of the Disclosure Statement, Ms. Morales is not waiving or otherwise giving up any of her rights with respect to her claim. See id. at 87:11–16; see also Hr’g Tr., April 10, 2025, at 33:12–37:16 [ECF No. 7385] (explaining to Ms. Morales that the Disclosure Statement deals with adequate information, the Plan deals with, among other things, how different classes of creditors will be treated, and that Ms. Morales is not waiving any of her rights by waiting to object to the Disclosure Statement or Plan, as applicable). At the conclusion of the February 2025 Hearing, the Court indicated it

would take Ms. Morales’ most recent filings under advisement and issue a ruling. See Hr’g Tr., February 25, 2025, at 93:17–24. This is that ruling. I. Prior Filings Before turning to the Current Motions, it is helpful to provide a brief history of Ms. Morales’ prior filings that provide context to the Current Motions. a.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Chateaugay Corp.
104 B.R. 622 (S.D. New York, 1989)
Manix Energy, Ltd. v. James (In Re James)
300 B.R. 890 (W.D. Texas, 2003)
Murray v. Donlan
77 A.D.2d 337 (Appellate Division of the Supreme Court of New York, 1980)
Cabrera v. Schafer
178 F. Supp. 3d 69 (E.D. New York, 2016)
Harrington v. Purdue Pharma L.P.
603 U.S. 204 (Supreme Court, 2024)

Cite This Page — Counsel Stack

Bluebook (online)
Purdue Pharma L.P., Counsel Stack Legal Research, https://law.counselstack.com/opinion/purdue-pharma-lp-nysb-2025.